Related Experiment Videos

[Metabolism of histamine in patients with coronary atherosclerosis]

Voprosy Meditsinskoi Khimii
|May 1, 1975
PubMed

Insights

Histamine metabolism is altered in coronary atherosclerosis. Treatments targeting histamine pathways improve outcomes and reduce angina attacks in patients with this condition.

Area of Science:

  • Biochemistry
  • Cardiology
  • Pharmacology

Context:

  • Coronary atherosclerosis involves complex physiological changes.
  • Histamine and its metabolic pathways play a role in cardiovascular function.
  • Understanding these roles is crucial for effective treatment.

Purpose:

  • To investigate histamine metabolism in patients with coronary atherosclerosis stages I and III.
  • To correlate histamine levels and enzyme activities with disease severity and angina attacks.
  • To evaluate the efficacy of antihistamine and desensitizing agents.

Summary:

  • In stage I coronary atherosclerosis, histamine levels and diaminooxidase activity increase during angina, while histidine decarboxylase and antihistamine factors remain normal.
  • In stage III, increased degranulated basophils and histidine decarboxylase activity, alongside decreased histaminopexy and antihistamine factors, are observed during angina.
  • A lack of correlation between blood histamine and diaminooxidase activity may lead to hyperhistaminaemia and increased urinary histamine excretion.

Impact:

  • Findings highlight the dysregulation of histamine metabolism in coronary atherosclerosis.
  • Antihistamine and desensitizing drugs, combined with vasodilators, enhance therapeutic effects.
  • These treatments reduce angina frequency, accelerate clinical improvement, and normalize histamine metabolism.

Related Concept Videos